

Author Index

Abdollahi M
5(2), 215–222

Ahmad S
5(2), 139–144

Ahrén B
5(1), 79–90

Aktas S
5(1), 99–108

Anderson JL
5(2), 125–128

Arlen PM
5(1), 1–2

Arya R
ary

Balaratnam S
5(2), 151–157

Brenner B
5(2), 123–124

Carlquist JF
5(2), 125–128

Chen JJ
5(2), 203–214

Cohen AT
5(2), 151–157

Culig Z
5(1), 47–56

Dahut W
5(1), 57–61

Das P
5(2), 139–144

Dashtipour K
5(2), 203–214

Davies J
5(1), 37–45

Del Vecchio L
5(1), 91–98

Dieter RS
5(2), 139–144

Drummond A
5(2), 195–197

Falanga A
5(2), 145–147

Fassiadis N
5(2), 151–157

Fitzmaurice DA
5(2), 129–131

Gulley JL
5(1), 3–5

Hardev P
5(1), 37–45

Harenberg J
5(2), 177–192

Hobisch A
5(1), 47–56

Hoffman R
5(2), 149–150

Ismail M
5(1), 37–45

Jellinger KA
5(2), 237–255

Karakunnel J
5(1), 57–61

Kumar S
5(2), 223–235

Kyprianou N
5(1), 7–11

Larijani B
5(2), 215–222

Lee RJ
5(1), 63–72

Legg L
5(2), 195–197

Lew MF
5(2), 203–214

Lip GYH
5(2), 139–144

Locatelli F
5(1), 91–98

Lois K
5(2), 223–235

Malik A
5(1), 109–117

Mandapaka S
5(2), 139–144

Meyer G
5(2), 159–167

Mouraviev P
5(1), 25–36

Nanjundappa A
5(2), 139–144

Patel RK
5(2), 169–175

Planquette B
5(2), 159–167

Polascik TJ
5(1), 25–36

Pozzoni P
5(1), 91–98

Salari P
5(2), 215–222

Sanchez O
5(2), 159–167

Smith MR
5(1), 63–72

Taggar JS
5(2), 139–144

Uzun G
5(1), 99–108

Vaidya V
5(1), 109–117

Yildiz S
5(1), 99–108

Compound Index

Acenocoumarol
5(2), 177–192

Adrostenedione
5(1), 47–56

Amitriptyline
5(2), 203–214

Apixaban
5(2), 177–192

Argatroban
5(2), 149–150

Atomoxetine
5(1), 109–117

Atrasentan
5(1), 57–61

Bevacizumab
5(1), 57–61

Bicalutamide
5(1), 47–56

Bisphosphonates
5(1), 63–72

Bombesin
5(1), 47–56

Bortezomib
5(1), 57–61

Bupropion
5(2), 203–214

Cediranib
5(1), 57–61

Citalopram
5(2), 203–214

Clomipramine
5(2), 203–214

Darbepoetin alpha
5(1), 91–98

D-fenfluramine
5(1), 109–117

Docetaxel
5(1), 57–61

Doxepin
5(2), 203–214

Enoxaparin
5(2), 177–192

Enoxaparin
5(2), 149–150

Epoetin alpha
5(1), 91–98

Epoetin beta
5(1), 91–98

Epoetin delta
5(1), 91–98

Escitalopram
5(2), 203–214

Estramustine
5(1), 57–61

fluazetil
5(2), 237–255

APPENDICES

Cumulative indices for 2008

Fluoxetine	Metformin	Protamine	Topiramate
5(2), 203–214	5(1), 79–90	5(2), 177–192	5(1), 79–90
Fluramine	Methamphetamine	Rasagiline	Trazodone
5(2), 223–235	5(2), 237–255	5(2), 203–214	5(2), 203–214
Fluvoxamine	Mianserin	Rimonabant	Venlafaxine
5(2), 203–214	5(2), 203–214	5(2), 223–235	5(2), 203–214
Folate	Mirtazapine	Rivaroxaban	Vildagliptin
5(2), 215–222	5(2), 203–214	5(2), 177–192; 5(2), 149–150	5(1), 79–90
Fondaparinux	Nefazodone	Ropinirole	Vitamin D
5(2), 149–150	5(2), 203–214	5(2), 203–214	5(1), 57–61
Heparin	Nortriptyline	Selegiline	Warfarin
5(2), 177–192	5(2), 203–214	5(2), 203–214	5(2), 125–128; 5(2), 129–131;
Hydroxyflutamide	Orlistat	Sibutramine	5(2), 177–192
5(1), 47–56	5(2), 223–235	5(2), 223–235	Xinlay™
Idraparinux	Orskolin	Sorafenib	see Atrasentan
5(2), 177–192	5(1), 47–56	5(1), 57–61	Zoledronic acid
Insulin	Otamixaban	Sulphonylurea	5(1), 63–72
5(1), 79–90	5(2), 177–192	5(1), 79–90	Zometa
Ketoconazole	Pamidronate	Sunitinib	see zoledronic acid
5(1), 47–56	5(1), 63–72	5(1), 57–61	
Lepirudin	Paroxetine	Thalidomide	
5(2), 149–150	5(2), 203–214	5(1), 57–61	
Levodopa	Pramipexole	Thiazolidinedione	
5(2), 237–255; 5(2), 203–214	5(2), 203–214	5(1), 79–90	
L-threo-dops	Prednisone	Topamax®	
5(2), 237–255	5(1), 57–61	see topiramate	